KOREA WHO

Lee Won-jik is the CEO of Lotte Biologics and also serves as the head of its U.S. subsidiary. He is focused on enhancing the company's contract development and manufacturing (CDMO) capabilities, securing clients, and positioning Lotte Biologics for success in its early stages.

Born on August 4, 1977, Lee Won-jik graduated from the Molecular and Cell Biology Department at the University of California, Berkeley.

He previously worked at global pharmaceutical companies Kyron (now Novartis Vaccines) and Bristol-Myers Squibb (BMS).

Lee joined Samsung Electronics' New Business Development Division and played a role in the launch of Samsung Biologics. He was appointed head of the DP (finished pharmaceutical products) division at Samsung Biologics upon its establishment.

After joining Lotte Holdings as the head of the New Growth Team 2, he prepared for the CDMO business entry and was later appointed CEO of Lotte Biologics when it was founded.

He aims to position Lotte Biologics among the top 10 global CDMO companies by 2030 and is undertaking a large-scale investment for facility expansion.

Lee Won-jik is a rare 40-something CEO within Lotte Group.

#LeeWonJik #LotteBiologics #CDMO #Pharmaceuticals #Leadership